An unmet need exists for effective glucocorticoid-sparing agents for the treatment of giant cell arteritis (GCA). Tocilizumab, the first intervention to demonstrate substantial therapeutic benefits for patients with newly diagnosed or relapsing GCA, is changing the landscape of treatment and ushering in a new era of biologic therapy.
Refers to Stone J.H. et al. Trial of tocilizumab in giant-cell arteritis. N. Engl. J. Med.377, 317-328 (2017)